Key facts
- It has raised $500K; the latest was Seed Round in Mar 2026.
- Notable investors include Y Combinator, Pioneer Fund.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Ditto Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Ditto Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ditto Bio
Developer of biotechnology designed for autoimmune disease therapies. The company's platform uses parasite-derived proteins, applies artificial intelligence for protein identification, incorporates evolutionary biology insights, and validates candidates through laboratory testing, enabling pharmaceutical companies, healthcare providers, and research institutions to discover novel treatments, expand therapeutic options, and improve management of autoimmune conditions with biologically informed drug discovery approaches.
- Sector
- Healthcare
- HQ
- Albany, CA, United States
- Founded
- 2025
- Employees
- 5
- Website
- dittobio.com/
- Ownership
- Privately Held (backing)
Ditto Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ditto Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ditto Bio in its N-PORT filings yet. We sweep new filings monthly.